Prothena Corporation plc has released a presentation detailing its ongoing efforts in developing life-saving therapies for diseases related to protein dysregulation, such as Alzheimer's disease, Parkinson's disease, and transthyretin amyloidosis. The presentation highlights the company's focus on therapeutics engineered to eliminate pathogenic proteins while preserving normal biology, utilizing a biology-directed engine for disease-driven antibody engineering. It outlines multiple clinical programs, including three partnered Phase 2 programs and one wholly-owned Phase 1 program. Prothena has established strong collaborations with partners like Bristol Myers Squibb, Novo Nordisk, and Roche. The presentation also emphasizes the global impact of neurodegenerative diseases and the economic burden they pose. You can access the full presentation through the link below.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.